MedTrace Logo

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2

NCT03802526 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2019-11-29

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics and safety/tolerability between NVP-1805-R1 and NVP-1805-R2

Conditions

  • Healthy

Interventions

DRUG

NVP-1805-R1

1 tablet, multiple oral dosing

DRUG

NVP-1805-R2

1 tablet, multiple oral dosing

DRUG

NVP-1805-R1 and NVP-1805-R2

NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing

Sponsors & Collaborators

  • NVP Healthcare

    lead INDUSTRY

Principal Investigators

  • Dong Sung Shin, M.D. · Gachon University Gil Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-03
Primary Completion
2019-07-04
Completion
2019-09-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03802526 on ClinicalTrials.gov